Why did GAAP EPS fall so sharply while adjusted EPS rose?

GAAP EPS of $4.54 (vs. $5.82) absorbed a $1.225 billion pre-tax loss on the sale of subsidiaries and held-for-sale South American operations, plus $1.1 billion in total cyberattack effects. Adjusted EPS of $6.80 (vs. $6.14) excludes South American impacts, direct cyberattack response costs, and intangible amortization, while still including $0.28 per share of Change Healthcare business disruption impacts.

Did UnitedHealth change its full-year 2024 outlook?

Yes, on a GAAP basis. The GAAP EPS outlook was set at $15.95 to $16.40 to reflect held-for-sale South American operations and estimated cyberattack impacts. The adjusted EPS outlook of $27.50 to $28.00 was affirmed, absorbing an estimated $0.60 to $0.70 per share of business disruption impacts, up $0.30 per share since the prior quarter.

How large are the ongoing cyberattack costs and what drives the increase?

Management estimates full-year 2024 total cyberattack impacts at $1.90 to $2.05 per share. Direct response costs are now $1.30 to $1.35 per share, up $0.40 to $0.45, driven by financial support for care providers and consumer notification costs. Business disruption impacts are estimated at $0.60 to $0.70 per share.

Is the core business still growing, and is medical cost pressure easing?

Core growth remained strong, with commercial domestic consumers served up 2.3 million year to date to 29.6 million, Optum Rx revenue up 13%, and Optum Health revenue up 13%. However, the medical care ratio rose to 85.1% from 83.2%, reflecting provider accommodations, Medicare funding reductions, reserve effects, and mix, so medical cost pressure remains a key watch item.

What is the status of the South American exit?

The company completed the sale of its larger Brazilian operations in the first quarter of 2024 and intends to sell its remaining South American operations, now classified as held for sale. Total South American impacts in Q2 were $1.28 per share, mostly non-cash and driven by cumulative foreign currency losses. The sale is subject to the risks noted in the forward-looking statements.

UNH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 16, 2024. Cited figures are marked; the original filing is the authoritative source.

UnitedHealth Group's Q2 2024 results (reported July 16, 2024) show revenue of $98.9 billion^a, up nearly $6 billion year over year, led by Optum and UnitedHealthcare.

Reported GAAP diluted EPS was $4.54^b, down from $5.82 a year earlier, reflecting a $1.3 billion-plus pre-tax loss tied to the classification of the remaining South American operations as held for sale and cyberattack costs. Adjusted EPS was $6.80, up from $6.14, excluding South American impacts, direct cyberattack response costs, and intangible amortization, while including $0.28 per share of Change Healthcare business disruption impacts. Cash flow from operations was $6.7 billion for the quarter, or 1.5x net income.

The company lowered its full-year 2024 GAAP EPS outlook to $15.95 to $16.40^c (from prior guidance implied by the South America and cyberattack charges), but affirmed its adjusted EPS outlook of $27.50 to $28.00. Management expects total full-year cyberattack impacts of $1.90 to $2.05 per share, with direct response costs rising by $0.40 to $0.45 per share to support care providers and consumer notification, and business disruption impacts of $0.60 to $0.70 per share. The reported medical care ratio rose to 85.1% from 83.2%, driven by care provider accommodations, Medicare funding reductions, and mix, and no favorable reserve development was recognized in the quarter.

For investors, the key questions are the durability of the cyberattack recovery and cost burden, the pace and proceeds of the South American exit, and whether medical cost trends stabilize. The quarter's growth in Optum Rx, Optum Health, and commercial domestic enrollment supports the core franchise, while the affirmed adjusted outlook signals management's confidence despite elevated one-time costs.

02—Key points

Key Highlights

Revenue of $98.9 billion, up nearly $6 billion year over year, led by Optum (Optum revenue $62.9 billion, up over $6 billion) and UnitedHealthcare ($73.9 billion).
GAAP diluted EPS of $4.54 vs. $5.82 a year earlier; adjusted EPS of $6.80 vs. $6.14, excluding South American impacts and cyberattack direct response costs.
Full-year 2024 adjusted EPS outlook affirmed at $27.50 to $28.00, while GAAP EPS outlook was updated to $15.95 to $16.40 for South America and cyberattack effects.
Total cyberattack impacts of $0.92 per share in Q2, with full-year 2024 impacts now estimated at $1.90 to $2.05 per share, including direct response costs of $1.30 to $1.35 (up $0.40 to $0.45).
Medical care ratio of 85.1% vs. 83.2% a year earlier, with 65 basis points of impacts from provider accommodations and South American actions; no favorable reserve development recognized.
Cash flow from operations of $6.7 billion in Q2, or 1.5x net income; dividend raised 12%, the 15th consecutive year of double-digit increases.
Over $9 billion in advance funding and interest-free loans provided to care providers; Change Healthcare services largely restored, and the company plans to sell its remaining South American operations.

03—Questions

Frequently Asked Questions

Why did GAAP EPS fall so sharply while adjusted EPS rose?
GAAP EPS of $4.54 (vs. $5.82) absorbed a $1.225 billion pre-tax loss on the sale of subsidiaries and held-for-sale South American operations, plus $1.1 billion in total cyberattack effects. Adjusted EPS of $6.80 (vs. $6.14) excludes South American impacts, direct cyberattack response costs, and intangible amortization, while still including $0.28 per share of Change Healthcare business disruption impacts.
Did UnitedHealth change its full-year 2024 outlook?
Yes, on a GAAP basis. The GAAP EPS outlook was set at $15.95 to $16.40 to reflect held-for-sale South American operations and estimated cyberattack impacts. The adjusted EPS outlook of $27.50 to $28.00 was affirmed, absorbing an estimated $0.60 to $0.70 per share of business disruption impacts, up $0.30 per share since the prior quarter.
How large are the ongoing cyberattack costs and what drives the increase?
Management estimates full-year 2024 total cyberattack impacts at $1.90 to $2.05 per share. Direct response costs are now $1.30 to $1.35 per share, up $0.40 to $0.45, driven by financial support for care providers and consumer notification costs. Business disruption impacts are estimated at $0.60 to $0.70 per share.
Is the core business still growing, and is medical cost pressure easing?
Core growth remained strong, with commercial domestic consumers served up 2.3 million year to date to 29.6 million, Optum Rx revenue up 13%, and Optum Health revenue up 13%. However, the medical care ratio rose to 85.1% from 83.2%, reflecting provider accommodations, Medicare funding reductions, reserve effects, and mix, so medical cost pressure remains a key watch item.
What is the status of the South American exit?
The company completed the sale of its larger Brazilian operations in the first quarter of 2024 and intends to sell its remaining South American operations, now classified as held for sale. Total South American impacts in Q2 were $1.28 per share, mostly non-cash and driven by cumulative foreign currency losses. The sale is subject to the risks noted in the forward-looking statements.

04—Continue

← View all 8-K filings